Skip to content


Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Bill Steinman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

Quick look at Big Pharma’s U.S. rap sheet

Recent turbulence in China for drug makers follows big problems for members of the industry in the United States, where they’ve paid billions in criminal fines and civil penalties.

Here’s a quick rundown of their U.S. rap sheet:

May 2012
Fined $1.5 billion for illegal promotion of the antipsychotic drug Depakote.

December 2012
Paid $762 million fine to resolve criminal and civil charges for illegal promotion of Aranesp, a drug to treat anemia.

April 2010
Fined $520 million for illegal promotion of antipsychotic drug Seroquel.

Boehringer Ingelheim
October 2012
Paid $95 million for wrongful promotion of Aggrenox, Atrovent, Combivent, and Micardis.

Eli Lilly
Jan 2009
Fined $1.42 billion for off-label promotion of the antipsychotic Zyprexa. In 2012, Eli Lilly paid $29 million to settle FCPA charges with the SEC.

July 2012
Fined $3 billion for illegal promotion of drugs and failure to report safety data. Pleaded guilty to misbranding the drug Paxil and failing to disclose safety information about the diabetes drug Avandia to the FDA. Former GSK manager-turned-whistleblower Cheryl Eckard awarded $96 million for the GSK payout.

November 2011
Fined $950 million for illegal promotion of the painkiller Vioxx.

September 2009
Fined $2.3 billion after pleading guilty to misbranding the painkiller Bextra with “the intent to defraud or mislead.” In 2012, Pfizer paid $60 million to the DOJ and SEC to resolve FCPA offenses.

December 2012
Paid $109 million for giving doctors free samples and net-back deals while also inflating prices for government programs.

Source for non-FCPA data: ProPublica


Richard L. Cassin is the Publisher and Editor of the FCPA Blog. He can be contacted here.

Share this post


Comments are closed for this article!